Moleculin Biotech News

Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...

Yahoo Finance03:00 ET

Earnings Call Summary | Moleculin Biotech(MBRX.US) Q1 2024 Earnings Conference

The following is a summary of the Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript:Financial Performance:The company reported a decrease in Research & Development (R&D) expenses from $5

moomoo AI20:34 ET · Conference Call

Moleculin Biotech 1Q Loss/Shr $2.02 >MBRX

Moleculin Biotech 1Q Loss/Shr $2.02 >MBRX

Dow JonesMay 13 07:32 ET

Moleculin Biotech 1Q Research and Development Expense $4.3M >MBRX

Moleculin Biotech 1Q Research and Development Expense $4.3M >MBRX

Dow JonesMay 13 07:32 ET

Express News | Moleculin Biotech Inc - Cash Is Sufficient to Meet Its Projected Operating Requirements Into Q4 of 2024

ReutersMay 13 07:31 ET

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

– Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)–

Moleculin BiotechMay 13 00:00 ET

Express News | Moleculin Biotech Q1 EPS $(2.02) Beats $(3.53) Estimate

BenzingaMay 10 17:09 ET

Moleculin Biotech | 10-Q: Quarterly report

Futu NewsMay 10 16:38 ET · Announcements

Moleculin Biotech Secures Patent for Liposomal Drug Innovation

TipRanksMay 9 08:43 ET

Express News | Moleculin Biotech Inc - Annamycin Is Advancing Towards Pivotal Aml Study in 2024 and May Qualify for an Accelerated Approval Pathway

ReutersMay 9 08:30 ET

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Patent, once issued, will provide composition protection through 2040, with potential for additional term extensionAnnamycin is advancing towards pivotal AML study in 2024 and may qualify for an accel

Moleculin BiotechMay 9 00:00 ET

Moleculin Biotech Announces Upcoming Quarterly Financial Results

TipRanksMay 8 08:42 ET

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

HOUSTON, May 8, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-trea

Moleculin BiotechMay 8 00:00 ET

Moleculin Biotech Shares Corporate Update Online

TipRanksMay 7 16:23 ET

Moleculin Biotech Shares Upbeat Annamycin AML Trial Update

TipRanksMay 7 09:13 ET

Express News | Moleculin Biotech: Annamycin in Combination With Cytarabine (Annarac) Achieves Crc Rate of 62% (54% Cr) in 1(St) and 2(Nd) Line Aml Subjects (N=13)

ReutersMay 7 08:55 ET

Express News | Moleculin Reports Higher Aml Complete Remission (Cr) Rates and Significant Durability With Additional Interim Subject Data

ReutersMay 7 08:55 ET

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability With Additional Interim Subject Data

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line, wi

Moleculin BiotechMay 7 00:00 ET

Moleculin Biotech Hosts AML Clinical Insights Virtual Event

TipRanksMay 2 09:12 ET

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Com

Moleculin BiotechMay 2 00:00 ET